Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview

Author(s): Sourav Thakur , Bhupendra Singh , Vijay Mishra* , Nishika Yadav , Namita Giri , Pardeep Sharma , Ankit Saini , Lavi K. Garg .

Journal Name: Recent Patents on Drug Delivery & Formulation

Volume 13 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Asthma is a common ailment with a larger circadian difference. Nocturnal Asthma (NA) is an inconstant exacerbation of asthmatic condition related to the rise in warning sign during the night time and there is a need for its treatment addressing air route alertness and decline in lung functions. These symptoms are linked to sleep or known as circadian events. Chronotherapeutics is a management system based on an in-vivo drug accessibility programmed to check the rhythms of ailment in a direction to improve the therapeutic outcomes by suppressing the side effects. This review aims to provide an overview of NA, chronotherapeutics for the treatment of NA, bilayer tablets, and advanced techniques involved in the fabrication of bilayer tablets. The review also discusses some of the related patents.

Methods: Relevant literature about the latest developments and updated information related to NA, chronotherapeutics and bilayer tablets has been very widely searched on different biomedical literature programs such as Google, Web of Science, PubMed portals, etc. Bilayer tablet mediated chronotherapy has gained significant attention and consideration as it is developed and fabricated based on the body’s circadian rhythm. Bilayer tablets can deliver the bioactive compounds at an appropriate time, place as well as amount and site.

Results: Available literature advocated that the bilayer matrix tablet containing a single drug in the sustained release film and fast releasing film, may be beneficial for the chronic diseases like asthma, migraine, diabetes, hypertension and inflammation which usually require immediate as well as maintained therapeutic effect.

Conclusion: The application of nanotechnology in the arena of medicine will transform the diagnosis and treatment strategies of a wide range of diseases in the upcoming years. The findings of this review confirm the importance of bilayer tablet based chronotherapy in nocturnal asthma.

Keywords: Asthma, circadian rhythm, chronotherapeutics, bilayer tablet, migraine, hypertension.

[1]
Ohdo S. Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet 2007; 22: 3-14.
[2]
Smolensky MH, Lemmer B, Reinberg AE. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Del Rev 2007; 59: 852-82.
[3]
Ohdo S. Changes in toxicity and effectiveness with timing of drug administration. Drug Safety 2003; 26: 999-1010.
[4]
Zhang Y, Zhang Z, Wu F. A novel pulsed-release system based on swelling and osmotic pumping mechanism. J Control Release 2003; 89: 47-55.
[5]
Martin R. Nocturnal asthma: An overview. In: Martin R, Ed. Nocturnal asthma: Mechanisms and treatment. Mount Kisco, New York: Futura Publishing Co., Inc 1993; pp. 71-115.
[6]
Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. J Allergy Clin Immunol 2003; 112: 513-7.
[7]
Sawada T, Sako K, Fukui M, Yokohama S, Hayashi M. A new index, the core erosion ratio, of compression-coated timed-release tablets predicts the bioavailability of acetaminophen. Int J Pharm 2003; 265: 55-63.
[8]
Ozeki Y, Watanabe Y, Inoue S, Danjo K. Evaluation of the compression characteristics and physical properties of the newly invented one-step dry-coated tablets. Int J Pharm 2003; 267: 69-78.
[9]
Rane AB, Gattani SG, Kadam VD, Tekade AR. Formulation and evaluation of press coated tablets for pulsatile drug delivery using hydrophilic and hydrophobic polymers. Chem Pharm Bull 2009; 57: 1213-7.
[10]
Qureshi J, Amir M, Ahuja A, Baboota S, Ali J. Chronomodulated drug delivery system of salbutamol sulphate for the treatment of nocturnal asthma. Indian J Pharm Sci 2008; 70: 351-6.
[11]
Robert OC, Rupi KP, Ian WK. Novel sustained release microspheres for pulmonary drug delivery. J Control Release 2005; 104: 79-90.
[12]
Zhang Y, Zhang Z. Simple determination of terbutaline in dog plasma by column- switching liquid chromatography. J Chromatogr B 2004; 805: 211-4.
[13]
McEvoy GK. AHFS Drug Information, 2000: American Society of Health-System Pharmacists 2000.
[14]
Gohel MC. Modulation of active pharmaceutical material release from a novel ‘tablet in capsule system’containing an effervescent blend. J Control Release 2002; 79: 157-64.
[15]
Baojian W, Ningyun S, Xiuli W, Wei W. Characterization of 5-fluorouracil release from Hydroxypropylmethylcellulose compression coated tablets. Pharm Dev Techn 2007; 12: 203-10.
[16]
Wadke DA, Serajuddin ATM. Preformulation testing Pharmaceutical dosage forms: Tablets. 2nd ed. Marcel Dekker New York 1989.
[17]
Pramodkumar T, Shivakumar H. Novel core in cup buccoadhesive systems and films of terbutalinesulphate- development and in vitro evaluation. Asian J Pharm Sci 2006; 1: 175-87.
[18]
Wilson AM. The role of antihistamines in asthma management. Treat Respir Med 2006; 5: 149-58.
[19]
Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile drug delivery systems: An approach for controlled drug delivery. Indian J Pharm Sci 2006; 68: 295-300.
[20]
Ross AC, Macrae RJ, Walther M, Stevens HN. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol 2000; 52: 903-9.
[21]
Kumar AH, Kavitha K, Kumar SA, Kumar MR, Singh SJ. Novel approach of bilayer tablet technology- A review. Int J Pharm Chem Biol Sci 2013; 3: 887-93.
[22]
Spandana KMA, Kumar SKS, Parthiban S. Bilayer floating tablets - A review. Indian J Pharm Sci Res 2013; 3: 1-8.
[23]
Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52: 1145-9.
[24]
Debnath M. Bilayer tableting technology: An overview. J Pharm Res 2012; 5: 310-4.
[25]
Bhandari A, Bhatt GK, Kothiyal P, Gosain S. Bilayer tablet oral solid drug delivery system and challenges in the formulation: A review. Int J Pharm Res Dev 2012; 4: 29-44.
[26]
Pujara ND, Gokani RK, Paun JS. Bilayer tablet-an emerging trend. Int J Pharm Res Dev 2012; 4: 103-4.
[27]
Kale SS, Saste VS, Ughade PL, Baviskar DT. Bilayer tablet. Int J Pharm Sci Rev Res 2011; 9: 25-30.
[28]
Reddy TP, Rao VD, Kumar KR. Bi-layer technology- an emerging trend: A review. Int J Res Dev Pharm Life Sci 2013; 2: 404-11.
[29]
Islam MS, Reza S, Rahman H. In vitro release kinetics study of diltiazem hydrochloride from wax and kollidon SR based matrix tablets. Iran J Pharm Res 2010; 7: 101-8.
[30]
Kivelä L, Papadopoulos MR, Antypa N. Chronotype and psychiatric disorders. Curr Sleep Med Rep 2018; 4(2): 94-103.
[31]
Nainwal N. Chronotherapeutics- A chronopharmaceutical approach to drug delivery in the treatment of asthma. J Control Release 2012; 163(3): 353-60.
[32]
Khan I, Ul Haq Z, Shaheen A, et al. Systematic review and meta-analysis of association of β2-adrenergic receptor gene polymorphisms with nocturnal asthma. J Postgrad Med Inst (Peshawar-Pakistan) 2017; 31: 234-42.
[33]
Singh B, Saini G, Jhanwar B. Colon specific chronotherapeutic drug delivery for nocturnal asthma: Effect of eudragit enteric coating on matrix tablets of salbutamol sulphate. Int J Pharm Tech Res 2017; 10: 19-30.
[34]
Chaudhari SP, Chaudhari PM, Narawane S. Development and optimization of chronopharmaceutical drug delivery system for asthma. J Drug Deliv Ther 2016; 6: 25-33.
[35]
Popova T, Petkova V, Dimitrov M. Formulation approaches to pulsatile-release chronotherapeutical drug delivery system with montelukast sodium. World J Pharm Pharm Sci 2016; 5: 1-17.
[36]
Rana P, Patel M, Khetani N. Pulsatile drug delivery system of theophylline for the treatment of nocturnal asthma J Pharm S Bio- Sci Res 2015; 5: 579-88.
[37]
Pandey S, Mehta P, Patel H, Shah R, Gupta A, Mishra A. Novel time and site specific “tablets in capsule” system for nocturnal asthma treatment. J Pharm Investig 2014; 44: 381-90.
[38]
Alavoine L, Taillé C, Ball J, et al. Nocturnal asthma: Proof-of-concept open-label study with delayed-release prednisone. Pulmonary Ther 2015; 1: 43-52.
[39]
Merikanto I, Englund A, Kronholm E, et al. Evening chronotypes have the increased odds for bronchial asthma and nocturnal asthma. Chronobiol Int 2013; 31: 95-101.
[40]
Chang DS, Venzon D, Raut S, Klosner A, Intra J, Kahler ES. Bilayer tablets of B vitamins and process for preparing the same US20170281666A1 (2017).
[41]
Abebe A, Martin K, Patel JM, Desai D, Timmins P. Bilayer tablet formulations US20150238421A1 (2015).
[42]
Eisenreich W. Bilayer tablet of telmisartan and amlodipine US20060110450A1 (2006).
[43]
Seob BJ, Sun CB, Su-yeon K, et al. Bilayer tablets comprising bepotastine or its salt KR101731078B1 (2016).
[44]
Soon YC, Jong-Oh K, Wook TJ, Beom GJ, Jin KJ, Bong U. Loxoprofen oral bilayer tablet and preparation method thereof KR101750652B1 2017.
[45]
Lianming L, Qiáo H, Qiáo HY, et al. Tegafur gimeracil oteracil potassium sustained-release bilayer tablet and preparation method thereof CN106333933A (2016).
[46]
Hui Y, Gǎng WC. Bilayer tablet comprising metformin hydrochloride and its preparation method net englitazone CN107432869A (2016).
[47]
Xīn CZ, Lìjié X, Fāng LX, Kǎn H, Huìqín Z. Method for preparing telmisartan and amlodipine double-layer tablets CN106822112A 2017.
[48]
Fernández PA, Velada CJ, Kumar R, Álvarez FL. Tablets comprising mirabegron and solifenacin WO2017186593A1 (2017).
[49]
Fēng DY, Xìngdōng Z, Yè ZR, Liàng SL. Herba dendrobii double-layer tablet, and preparation method thereof CN107095969A (2017).
[50]
Türkyilmaz A, Pehlivan AN, Ayhan M, Demir I, Ramazanoglu G. Bilayer tablet formulations of montelukast and rupatadine WO2017182641A1 (2017).
[51]
Davar N, Ayer AD, Hwang PM, Shivanand P, Pollock BJ. Anti-asthma therapy US6224907B1 (2001).
[52]
Patel JD, Patel DT, Patel SD. Novel pulsatile drug delivery system US20170202786A1 (2017).
[53]
Durrington HJ, Farrow SN, Ray DW. Recent advances in chronotherapy for the management of asthma. Chronophysiol Ther 2014; 4: 125-35.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2019
Page: [74 - 82]
Pages: 9
DOI: 10.2174/1872211313666190227204127
Price: $58

Article Metrics

PDF: 36
HTML: 2
EPUB: 1
PRC: 1